Drozitumab is a human monoclonal antibody directed against DR5. DR5 is a ell surface receptor of the TNF-receptor superfamily that binds TRAIL and mediates apoptosis. Study showed that Drozitumab was effective against Rhabdomyosarcoma cell lines.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.